Skip to main content
Equibles
OCGN logo

OCGN · Ocugen, Inc. · Earnings Call Transcripts & Audio

Track OCGN — free

Use OCGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.06 +0.03 (+2.91%) At close · Sep 18
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“After evaluating these conditions and management's plans, the Company has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$359.46M
Shares
339.11M

Ocugen, Inc. Earnings Call Transcripts

Quarterly earnings calls for Ocugen, Inc. (OCGN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $643,000 −$21.48M '22 Q2 22-08-05 · $466,000 −$23.91M '22 Q3 22-11-08 · $879,000 −$22.39M '22 Q4 23-02-28 ▼11.4% $443,000 −$17.33M '23 Q1 23-05-05 ▼24.6% $485,000 −$23.07M '23 Q2 23-08-22 ▲693.8% $3.70M −$11.72M '23 Q3 23-11-09 ▲128.9% $1.01M −$11.92M '24 Q1 24-05-14 ▲135.3% $1.14M −$15.28M '24 Q2 24-08-08 ▼69.3% $1.14M −$12.97M '24 Q3 24-11-08 ▼45.8% $764,000 −$13.88M '24 Q4 25-03-05 ▲46.1% $1.48M −$15.35M '25 Q1 25-05-09 ▲20.3% $1.37M −$14.74M '25 Q2 25-08-01 ▲54.2% $1.75M −$20.05M '25 Q3 25-11-05 ▼125.3% $ −$17.71M '25 Q4 26-03-04 ▲3.5% $1.53M −$19.18M '26 Q1 26-05-05 LATEST ▲8.4% $1.49M −$24.88M '26 Q2 26-08-06
Conference
Investor event
2026-09-15
Ocugen, Inc. (OCGN) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-11
Ocugen, Inc. (OCGN) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call
Revenue
$1.49M
▲ 8.4% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Ocugen, Inc. (OCGN) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript
Confident tone OCU400 for retinitis pigmentosa (RP) Clinical milestones and timeline catalysts OCU410ST for Stargardt disease
Revenue
$1.53M
▲ 3.5% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript
Confident tone OCU410 (GA) Phase 2 data and Phase 3 initiation Rolling BLA submission for OCU400 in 2026 OCU400 Phase 3 Limelight trial enrollment complete
Revenue
$*
▼ 125.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript
Confident tone OCU400 Phase 3 retinitis pigmentosa Clinical trial enrollment and timelines OCU410 geographic atrophy / dry AMD
Revenue
$1.75M
▲ 54.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Confident tone OCU400 gene therapy for retinitis pigmentosa OCU410 for geographic atrophy / dAMD Regulatory designations and agency interactions
Revenue
$1.37M
▲ 20.3% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
Confident tone OCU410 dry AMD / geographic atrophy OCU400 RP gene therapy program Regulatory alignment with FDA and EMA
Revenue
$1.48M
▲ 46.1% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-05
Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript
Confident tone OCU410 Dry AMD / Geographic Atrophy OCU410ST Stargardt Disease OCU400 Retinitis Pigmentosa Phase 3
Revenue
$764,000*
▼ 45.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Confident tone OCU410 for Geographic Atrophy (ArMaDa Trial) OCU410ST for Stargardt Disease (GARDian Trial) OCU400 Phase 3 liMeliGhT Clinical Trial for RP
Revenue
$1.14M
▼ 69.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ocugen, Inc. (OCGN) Q2 2024 Earnings Call Transcript
Confident tone OCU400 Phase 3 RP program OCU410 geographic atrophy / dry AMD Expanded Access Program for RP
Revenue
$1.14M
▲ 135.3% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
Confident tone OCU400 Phase III liMeliGhT trial for RP/LCA OCU410/Ocu410ST for dry AMD and Stargardt Cell therapy platform and NeoCart
Revenue
$1.01M
▲ 128.9% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-11-09
Ocugen, Inc. (OCGN) Q3 2023 Earnings Call Transcript
Revenue
$3.70M
▲ 693.8% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-22
Ocugen, Inc. (OCGN) Q2 2023 Earnings Call Transcript
Revenue
$485,000
▼ 24.6% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Ocugen, Inc. (OCGN) Q1 2023 Earnings Call Transcript
Revenue
$443,000
▼ 11.4% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Ocugen, Inc. (OCGN) Q4 2022 Earnings Call Transcript
Revenue
$879,000*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Ocugen, Inc. (OCGN) Q3 2022 Earnings Call Transcript
Revenue
$466,000
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-05
Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Revenue
$643,000
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript
Revenue
$500,000
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-25
Ocugen, Inc. (OCGN) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-06
Ocugen, Inc. (OCGN) Q2 2021 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-18
Ocugen, Inc. (OCGN) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q2
2020-08-14
Ocugen, Inc. (OCGN) Q2 2020 Earnings Call Transcript
Revenue
$43,000
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-27
Ocugen, Inc. (OCGN) Q4 2019 Earnings Call
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1372299 CUSIP 67577C105 13F (30d) 4 filings 4 filers Visit website Investor relations